← Back to all signals
RESEARCH PAPER ANALYSIS

Choices of morbidity outcomes and concentration-response functions for health risk assessment of long-term exposure to air pollution.

AI interpretation is pending for this paper.

Open original publication →
PMID39045486
JournalEnvironmental epidemiology (Philadelphia, Pa.)
Publication Date2024-06-25
Ingested2026-08-02 12:02 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

BACKGROUND: Air pollution health risk assessment (HRA) has been typically conducted for all causes and cause-specific mortality based on concentration-response functions (CRFs) from meta-analyses that synthesize the evidence on air pollution health effects. There is a need for a similar systematic approach for HRA for morbidity outcomes, which have often been omitted from HRA of air pollution, thus underestimating the full air pollution burden. We aimed to compile from the existing systematic reviews and meta-analyses CRFs for the incidence of several diseases that could be applied in HRA. To achieve this goal, we have developed a comprehensive strategy for the appraisal of the systematic reviews and meta-analyses that examine the relationship between long-term exposure to particulate matter with an aerodynamic diameter smaller than 2.5 µm (PM2.5), nitrogen dioxide (NO2), or ozone (O3) and incidence of various diseases. METHODS: To establish the basis for our evaluation, we considered the causality determinations provided by the US Environmental Protection Agency Integrated Science Assessment for PM2.5, NO2, and O3. We developed a list of pollutant/outcome pairs based on these assessments and the evidence of a causal relationship between air pollutants and specific health outcomes. We conducted a comprehensive literature search using two databases and identified 75 relevant systematic reviews and meta-analyses for PM2.5 and NO2. We found no relevant reviews for long-term exposure to ozone. We evaluated the reliability of these studies using an adaptation of the AMSTAR 2 tool, which assesses various characteristics of the reviews, such as literature search, data extraction, statistical analysis, and bias evaluation. The tool's adaptation focused on issues relevant to studies on the health effects of air pollution. Based on our assessment, we selected reviews that could be credible sources of CRF for HRA. We also assessed the confidence in the findings of the selected systematic reviews and meta-analyses as the sources of CRF for HRA. We developed specific criteria for the evaluation, considering factors such as the number of included studies, their geographical distribution, heterogeneity of study results, the statistical significance and precision of the pooled risk estimate in the meta-analysis, and consistency with more recent studies. Based on our assessment, we classified the outcomes into three lists: list A (a reliable quantification of health effects is possible in an HRA), list B+ (HRA is possible, but there is greater uncertainty around the reliability of the CRF compared to those included on list A), and list B- (HRA is not recommended because of the substantial uncertainty of the CRF). RESULTS: In our final evaluation, list A includes six CRFs for PM2.5 (asthma in children, chronic obstructive pulmonary disease, ischemic heart disease events, stroke, hypertension, and lung cancer) and three outcomes for NO2 (asthma in children and in adults, and acute lower respiratory infections in children). Three additional outcomes (diabetes, dementia, and autism spectrum disorders) for PM2.5 were included in list B+. Recommended CRFs are related to the incidence (onset) of the diseases. The International Classification of Diseases, 10th revision codes, age ranges, and suggested concentration ranges are also specified to ensure consistency and applicability in an HRA. No specific suggestions were given for ozone because of the lack of relevant systematic reviews. CONCLUSION: The suggestions formulated in this study, including CRFs selected from the available systematic reviews, can assist in conducting reliable HRAs and contribute to evidence-based decision-making in public health and environmental policy. Future research should continue to update and refine these suggestions as new evidence becomes available and methodologies evolve.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Predisposing, Precipitating, Perpetuating, and Protective Factors Associated With Distress in the Siblings of Children With Cancer: A Systematic Review. Journal of pediatric hematology/oncology nursing 71.4 2 Germline POT1 variants are associated with long telomeres and an unexpected broad spectrum of malignancies. Genetics in medicine open 57.0 3 Risk Factors for Pouch Neoplasia in Patients With Inflammatory Bowel Disease: A Case-Control Study. Gastro hep advances 69.0 4 Neuroblastoma Metastasis to the Mandible in Children: A Case Report and Focused Narrative Review of Reported Cases. Children (Basel, Switzerland) 57.5 5 Proteomic Profiling of Bone Marrow Aspirates from Patients with Methotrexate- and Vincristine-Resistant B-Cell Acute Lymphoblastic Leukemia: A Retrospective Analysis. Pharmaceuticals (Basel, Switzerland) 71.7 6 A Tale of Two Cohorts: Comparing HPV Vaccination Barriers and Facilitators Among HIV-Negative and HIV-Positive Women in Tennessee. International journal of environmental research and public health 60.0 7 A Sanguinarine Analogue Targeting ROS Signaling Exhibits Anti-Tumour Effects by Inducing Apoptosis and Ferroptosis in Osteosarcoma. Antioxidants (Basel, Switzerland) 74.7 8 Prepubertal Screening for Testicular Adrenal Rest Tumors in Boys with Classic Congenital Adrenal Hyperplasia: Emerging Evidence and Practical Implications. Children (Basel, Switzerland) 57.0 9 Pharmacogenetic Predictors of Chemotherapy Treatment-Related Toxicities in Paediatric and Adolescent Acute Lymphoblastic Leukemia: A Systematic Review, Meta-Analysis and Literature-Based Candidate Prioritization. Pharmaceuticals (Basel, Switzerland) 85.98 10 [Opsoclonus Myoclonus Ataxia: Diagnostic pathway and immunosuppressive treatment in opsoclonus-myoclonus]. Medicina 68.04 11 [Sturge-Weber syndrome: comparative analysis between clinical manifestations and neuro-radiological findings]. Medicina 57.6 12 Image-Based Assessment of Anti-TNF Treatment Outcomes in Pediatric CRMO/CNO: A Single-Center Case Series. Children (Basel, Switzerland) 61.84 13 Understanding HPV Vaccine Uptake Among American Indian and Alaska Native College Students: A Scoping Review. International journal of environmental research and public health 58.7 14 Genetic Susceptibility to Anthracycline-Induced Cardiotoxicity in Australian Pediatric Cancer Patients: A Case-Control Study. JACC. Advances 54.62 15 Infection-Related Adverse Events of Tisagenlecleucel in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: A FAERS Pharmacovigilance Study. Children (Basel, Switzerland) 72.16 16 Catalase Defines Radiotherapy Resistance and a Therapeutic Vulnerability in Rhabdomyosarcoma. International journal of molecular sciences 64.88 17 Multidisciplinary Management of Pediatric Craniopharyngioma: From Diagnosis to Long-Term Outcomes. Biomedicines 67.4 18 Idiopathic Syringomyelia: A Systematic Scoping Review. Journal of clinical medicine 73.5 19 Beyond Oligodendroglioma: An Integrated Diagnostic Approach to CNS Tumors with Oligodendroglioma-like Morphology, with a Focus on Morphological Pitfalls, Immunoprofiles, and Molecular Signatures. International journal of molecular sciences 56.0 20 Diagnostic Intervals in Children, Adolescents and Young Adults with Primary Bone Sarcoma: A Systematic Review. Cancers 79.6 21 Next-Generation Sequencing Refines Diagnosis and Expands Precision Medicine Opportunities in Soft Tissue Sarcomas. International journal of molecular sciences 68.64 22 Closing the evidence gap: why childhood cancer research must include fathers. Public health reviews 28.5 23 Prognostic implications of CD123 in pediatric B-cell acute lymphoblastic leukemia: a single-center retrospective analysis. Frontiers in pediatrics 79.8 24 Revisiting the hematological manifestations of vitamin B12 deficiency. Frontiers in nutrition 59.9 25 Efficacy and Safety of Adjusting Antimicrobial Therapy in Episodes of Fever and Neutropenia Catalogued as Fever of Unknown Origin in Children with Cancer: A Randomized Clinical Trial. Antibiotics (Basel, Switzerland) 76.64 26 Health Economic Assessment of PM2.5 Originating from Residential Wood Combustion-A Case Study in Northern Sweden. International journal of environmental research and public health 47.7 27 Nanotechnology in Pediatric Neurology: Applications and Innovations. Pharmaceutics 77.9 28 Disparities in Area Socioeconomic Development and Pediatric Cancer Survival in Romania-A National Pediatric Registry Study on Multiple Geographic Levels. Cancers 71.62 29 Pediatric B-Cell Acute Lymphoblastic Leukemia: Comprehensive Genomic Characterization Including SNP-Array and Analysis of Relapse Risk. Cancers 64.92 30 Precision Medicine in Dermatology: MEK Inhibition and MAPK Pathway Modulation for Congenital Melanocytic Nevi. Biomedicines 70.44 31 Pancreatoblastoma: A Descriptive and Comparative Analysis with Pancreatic Ductal Adenocarcinoma Using SEER Data. Cancers 63.1 32 Cytokines in First-Episode Psychosis: Implications for Pathophysiology: A Narrative Literature Review. Brain sciences 57.0
PATIENT-FRIENDLY SUMMARY

Choices of morbidity outcomes and concentration-response functions for health risk assessment of long-term exposure to air pollution.

For education only—not personal medical advice.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic